keyword
MENU ▼
Read by QxMD icon Read
search

Vedolizumab

keyword
https://www.readbyqxmd.com/read/29667146/cost-effectiveness-analysis-of-crohn-s-disease-treatment-with-vedolizumab-and-ustekinumab-after-failure-of-tumor-necrosis-factor-%C3%AE-antagonist
#1
Przemysław Holko, Paweł Kawalec, Andrzej Pilc
OBJECTIVE: The aim was to evaluate the cost-effectiveness of Crohn's disease (CD) treatment with vedolizumab and ustekinumab after failure of therapy with tumor necrosis factor-α antagonists (anti-TNFs). METHODS: The Markov model incorporated the lifetime horizon, synthesis-based estimates of biologics' efficacy in relation to anti-TNF exposure, and administration of biologics reflecting clinical practice (e.g., sequence of biologics, retreatment, 12-month treatment)...
April 17, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29665045/high-body-mass-index-is-associated-with-increased-risk-of-treatment-failure-and-surgery-in-biologic-treated-patients-with-ulcerative-colitis
#2
S Kurnool, N H Nguyen, J Proudfoot, P S Dulai, B S Boland, N Vande Casteele, E Evans, E L Grunvald, A Zarrinpar, W J Sandborn, S Singh
BACKGROUND: Though pharmacokinetic studies suggest accelerated biologic drug clearance with increasing body weight, evidence of obesity's impact on clinical outcomes in biologic-treated patients with ulcerative colitis (UC) is inconsistent. AIMS: To evaluate the impact of obesity on real world response to biological therapy in patients with UC. METHODS: In a single-centre retrospective cohort study between 2011-2016 of biologic-treated patients with UC, we evaluated treatment response by baseline body mass index (BMI)...
April 17, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29644739/editorial-monitoring-vedolizumab-trough-serum-concentration-in-inflammatory-bowel-disease-following-the-fate-of-anti-tnf-alpha-agents
#3
EDITORIAL
M Fragaki, K Karmiris
No abstract text is available yet for this article.
May 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29623442/therapeutic-drug-monitoring-in-pediatric-inflammatory-bowel-disease
#4
REVIEW
Nicholas Carman, David R Mack, Eric I Benchimol
PURPOSE OF REVIEW: Therapeutic drug monitoring (TDM) has emerged as a useful tool to optimize the use of drug therapies in adults with inflammatory bowel disease (IBD), including both Crohn's disease (CD) and ulcerative colitis (UC), especially during the use of biological therapies, for which the pharmacokinetics and pharmacodynamics are highly variable among patients. Fewer data exist in children. This review examines the current literature on TDM in pediatric IBD. RECENT FINDINGS: Drug clearance is affected by a number of patient and disease factors...
April 5, 2018: Current Gastroenterology Reports
https://www.readbyqxmd.com/read/29614303/a-unique-infusion-reaction-to-vedolizumab-in-a-patient-with-crohn-s-disease
#5
Stephanie L Gold, Cynthia Magro, Ellen Scherl
No abstract text is available yet for this article.
March 31, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29611077/immunephenotype-predicts-response-to-vedolizumab-integrating-clinical-and-biochemical-biomarkers-in-the-treatment-of-inflammatory-bowel-diseases
#6
EDITORIAL
Stefano Fiorucci, Michele Biagioli, Eleonora Distrutti
No abstract text is available yet for this article.
April 2, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29610507/vedolizumab-as-a-novel-treatment-for-refractory-collagenous-colitis-a-case-report
#7
Kelly C Cushing, Mari Mino-Kenudson, John Garber, Paul Lochhead, Hamed Khalili
No abstract text is available yet for this article.
April 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29606936/vedolizumab-as-a-potential-culprit-in-the-development-of-ovarian-teratoma
#8
Judy A Trieu, Mohammad Bilal, Gurinder Luthra
Vedolizumab is a new humanized monoclonal antibody that has been reserved for those with moderate-to-severe Crohn's disease and ulcerative colitis who have failed immunomodulator and TNF-α antagonist therapy, and for those who have an increased risk for developing progressive multifocal leukoencephalopathy. Because it targets gastrointestinal tract-specific lymphocytes, meta-analyses and integrated studies have shown that vedolizumab causes fewer extraintestinal adverse effects, such as opportunistic infections and malignancies, compared with anti-TNF therapies...
September 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29606934/vedolizumab-treatment-for-ulcerative-colitis-in-an-elderly-multimorbid-patient-with-hemophilia-a
#9
Holger Schäffler, Astrid Huth, Georg Lamprecht, Olaf Anders
The treatment of inflammatory bowel diseases (IBD) can be challenging, especially in elderly multimorbid patients. Since incidence and prevalence rates of IBD are rising steadily, treatment of older patients with relevant and also rare comorbidities will be of increasing relevancy for caregivers. Here we report on a 74-year-old multimorbid patient with severe ulcerative colitis (UC) and hemophilia A. Because of the chronic active disease, therapy with a tumor necrosis factor-α inhibitor was started. He suffered from a severe infectious complication (pneumonia) under therapy with infliximab...
September 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29596982/vedolizumab-treatment-may-reduce-steroid-burden-and-improve-histology-in-patients-with-eosinophilic-gastroenteritis
#10
Hannah P Kim, Craig C Reed, Hans H Herfarth, Evan S Dellon
No abstract text is available yet for this article.
March 26, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29589185/contemporary-management-of-ulcerative-colitis
#11
REVIEW
Rohini Vanga, Millie D Long
PURPOSE OF REVIEW: We discuss the newest evidence-based data on management of ulcerative colitis (UC). We emphasize risk-stratification, optimizing medical therapies, and surgical outcomes of UC. RECENT FINDINGS: Recent medical advances include introduction of novel agents for UC. Vedolizumab, an anti-adhesion molecule, has demonstrated efficacy in moderate to severe UC. Tofacitinib, a small molecule, has also demonstrated efficacy. Data on optimization of infliximab show the superiority of combination therapy with azathioprine over monotherapy with infliximab or azathioprine alone...
March 27, 2018: Current Gastroenterology Reports
https://www.readbyqxmd.com/read/29576495/the-real-world-effectiveness-of-vedolizumab-on-intestinal-and-articular-outcomes-in-inflammatory-bowel-diseases
#12
Fabio Salvatore Macaluso, Rosalba Orlando, Walter Fries, Mariangela Scolaro, Antonio Magnano, Dario Pluchino, Maria Cappello, Gaetano Cristian Morreale, Sebastiano Siringo, Antonino Carlo Privitera, Concetta Ferracane, Nunzio Belluardo, Nadia Alberghina, Marco Ventimiglia, Giulia Rizzuto, Sara Renna, Mario Cottone, Ambrogio Orlando
BACKGROUND: The effectiveness of vedolizumab in real-world practice is under evaluation, while its role in inflammatory bowel disease-associated spondyloarthritis is still unclear. AIMS: To report real-world data about the effectiveness of vedolizumab on intestinal and articular symptoms after 10 and 22 weeks of treatment. METHODS: Web-based data from the cohort of the Sicilian Network for Inflammatory Bowel Disease (SN-IBD) were extracted to perform a prospective multicentre observational study...
March 1, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29562271/vedolizumab-as-induction-and-maintenance-for-inflammatory-bowel-disease-12-month-effectiveness-and-safety
#13
Britt Christensen, Ruben J Colman, Dejan Micic, Peter R Gibson, Sarah R Goeppinger, Andres Yarur, Christopher R Weber, Russell D Cohen, David T Rubin
Background: Vedolizumab is approved for moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). We present prospective, 1-year data of the real-world effectiveness and safety of vedolizumab in inflammatory bowel disease. Methods: Consecutive patients receiving vedolizumab for treatment of UC or CD with at least 14 weeks of follow-up, regardless of outcome, were included. Patients had clinical activity scores (Harvey-Bradshaw Index [HBI] or Simple Clinical Colitis Activity Index [SCCAI]) and inflammatory markers prospectively measured at baseline and weeks 14, 30, and 52...
March 19, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29562246/corrigendum-vedolizumab-in-paediatric-inflammatory-bowel-disease-a-retrospective-multi-centre-experience-from-the-paediatric-ibd-porto-group-of-espghan
#14
Oren Ledder, Amit Assa, Arie Levine, Johanna C Escher, Lissy de Ridder, Frank Ruemmele, Neil Shah, Ron Shaoul, Victorien M Wolters, Astor Rodrigues, Holm H Uhlig, Carsten Posovszky, Kaija-Leena Kolho, Christian Jakobsen, Shlomi Cohen, Dror S Shouval, Tim de Meij, Javier Martin-de-Carpi, Lisa Richmond, Jiri Bronsky, Mira Friedman, Dan Turner
No abstract text is available yet for this article.
March 17, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29560811/a-prospective-cohort-study-to-assess-the-relevance-of-vedolizumab-drug-level-monitoring-in-ibd-patients
#15
Hermann Schulze, Philip Esters, Franz Hartmann, Juergen Stein, Christina Christ, Michael Zorn, Axel Dignass
BACKGROUND: Vedolizumab (VDZ) drug monitoring strategies in inflammatory bowel disease (IBD) patients have not been systematically investigated so far. We evaluated the correlation between VDZ trough levels (VTL) and the treatment response in IBD. METHODS: Fifty-one patients with active IBD on or starting a therapy with VDZ were enrolled in this prospective and observational single centre study. Disease activity indices, blood tests, and anthropometric parameters were assessed over a time period of 6 months...
March 21, 2018: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29556726/new-treatment-options-for-inflammatory-bowel-diseases
#16
REVIEW
Bram Verstockt, Marc Ferrante, Séverine Vermeire, Gert Van Assche
The advent of anti-TNF agents has dramatically changed the treatment algorithms for IBD in the last 15 years, but primarily and more importantly secondary loss of response is often observed. Fortunately , new treatment options have been actively explored and some have already entered our clinical practice. In the class of anti-cytokine agents, the anti-IL12/IL23 monoclonal antibodies (mAbs) have entered clinical practice with the anti-p40 mAb ustekinumab in Crohn's disease (CD). Also, more selective anti-IL23 agents (anti-p19) have shown efficacy and are being further developed, in contrast to agents inhibiting IL-17 downstream which have failed in clinical trials despite their clear efficacy in psoriasis (Verstockt et al...
March 19, 2018: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29545207/biological-therapies-in-inflammatory-bowel-disease-beyond-anti-tnf-therapies
#17
Konstantinos H Katsanos, Konstantinos Papamichael, Joseph D Feuerstein, Dimitrios K Christodoulou, Adam S Cheifetz
The pharmacological management of inflammatory bowel disease (IBD) over the last two decades has transitioned from reliance on aminosalycilates, corticosteroids and immunomodulators to earlier treatment with anti-tumor necrosis factor (anti-TNF) therapy. Nevertheless, 20-30% of patients discontinue anti-TNF therapy for primary non-response and another 30-40% for losing response within one year of treatment. These undesirable therapeutic outcomes can be attributed to pharmacokinetic (anti-drug antibodies and/or low drug concentrations) or pharmacodynamic issues characterized by a non-TNF driven inflammation...
March 12, 2018: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/29527316/outcome-of-tacrolimus-and-vedolizumab-after-corticosteroid-and-anti-tnf-failure-in-paediatric-severe-colitis
#18
Blaise Hamel, May Wu, Elizabeth O Hamel, Dorsey M Bass, K T Park
Background: Severe colitis flare from ulcerative colitis (UC) or Crohn's disease (CD) may be refractory to corticosteroids and antitumour necrosis factor (TNF) agents resulting in high colectomy rates. We aimed to describe the utility of tacrolimus to prevent colectomy during second-line vedolizumab initiation after corticosteroid and anti-TNF treatment failure in paediatric severe colitis. Methods: A retrospective cohort analysis was performed between 1 October 2014 and 31 October 2016 at a single tertiary care centre...
2018: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/29516018/emerging-role-of-vedolizumab-in-managing-refractory-immune-checkpoint-inhibitor-induced-enteritis
#19
Pietro Diana, Charoen Mankongpaisarnrung, Michael B Atkins, Jay C Zeck, Aline Charabaty
We report a 62-year-old white woman with metastatic choroidal melanoma who developed immune checkpoint inhibitor (ICI)-induced enteritis and grade 3 diarrhea refractory to steroids and infliximab. Her diarrhea quickly resolved after infusion of vedolizumab, and the patient was able to taper down steroids. Vedolizumab's mechanism of action and its gut specificity have the potential to reverse immune-induced enterocolitis without neutralizing or reversing the therapeutic benefit of ICI on the malignancy.
2018: ACG Case Reports Journal
https://www.readbyqxmd.com/read/29511561/cost-effectiveness-of-biological-treatment-sequences-for-fistulising-crohn-s-disease-across-europe
#20
Petra Baji, László Gulácsi, Valentin Brodszky, Zsuzsanna Végh, Silvio Danese, Peter M Irving, Laurent Peyrin-Biroulet, Stefan Schreiber, Fanni Rencz, Péter L Lakatos, Márta Péntek
Background: In clinical practice, treatment sequences of biologicals are applied for active fistulising Crohn's disease, however underlying health economic analyses are lacking. Objective: The purpose of this study was to analyse the cost-effectiveness of different biological sequences including infliximab, biosimilar-infliximab, adalimumab and vedolizumab in nine European countries. Methods: A Markov model was developed to compare treatment sequences of one, two and three biologicals from the payer's perspective on a five-year time horizon...
March 2018: United European Gastroenterology Journal
keyword
keyword
1883
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"